OXALIPLATIN INJECTION 5 MG — DIN 02454084
OXALIPLATIN : 5 MG · GENERIC MEDICAL PARTNERS INC · SOLUTION · wholesale supply in Canada
Health Canada status: APPROVED
What is OXALIPLATIN INJECTION?
OXALIPLATIN INJECTION 5 MG contains OXALIPLATIN : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02454084, held by GENERIC MEDICAL PARTNERS INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 25-Apr-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
How much does Oxaliplatin cost around the world?
Oxaliplatin is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 18 | 26 | SAR███.██ |
| South Africa | single exit price | 22 | 22 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 5 | 11 | CZK███.██ |
| United Arab Emirates | public | 6 | 8 | AED███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Romania | max producer price | 2 | 6 | RON███.██ |
| Australia | ex-manufacturer | 2 | 4 | AUD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | USD███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
90 pack listings across 67 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Oxaliplatin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Oxaliplatin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Oxaliplatin, across 22 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 1 | OXALIPLATIN INJECTION, TEVA-OXALIPLATIN INJECTION | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 1 | 1 | OXALIPLATIN INJECTION, USP | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | OXALIPLATIN INJECTION, USP | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | OXALIPLATIN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | OXALIPLATIN INJECTION | Sourceable in Canada |
| ACTAVIS PHARMA COMPANY | 3 | 0 | ACT OXALIPLATIN | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 3 | 0 | OXALIPLATIN FOR INJECTION, OXALIPLATIN INJECTION | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 3 | 0 | ELOXATIN | No marketed DIN |
| AURO PHARMA INC | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| GENERIC MEDICAL PARTNERS INC | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-OXALIPLATIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Oxaliplatin |
|---|---|
| ATC code | L01XA03 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02454084 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2454084 |
| Brand name | OXALIPLATIN INJECTION |
| Generic / active ingredient | OXALIPLATIN : 5 MG |
| Market authorization holder | GENERIC MEDICAL PARTNERS INC |
| Health Canada schedule | Prescription |
| ATC code | L01XA03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XA |
| Current status | APPROVED |
| Status date | 25-Apr-2016 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Oxaliplatin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by DR REDDY'S LABORATORIES LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 22 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OXALIPLATIN | 5 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02444763 |
| OXALIPLATIN INJECTION | 5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02436957 |
| OXALIPLATIN INJECTION | 5 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02435071 |
| OXALIPLATIN INJECTION, USP | 5 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02457423 |
| OXALIPLATIN INJECTION, USP | 5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02458403 |
| ACT OXALIPLATIN | 100 MG | POWDER FOR SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02430533 |
| ACT OXALIPLATIN | 50 MG | POWDER FOR SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02430525 |
| ACT OXALIPLATIN | 5 MG | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | 02432617 |
| ELOXATIN | 5 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02296284 |
| ELOXATIN | 50 MG | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02296268 |
2 · Same class — other molecules in ATC L01XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Oxaliplatin | ACT OXALIPLATIN · ELOXATIN · OXALIPLATIN · OXALIPLATIN FOR INJECTION · +6 more | 22 | 5 | Yes |
| Cisplatin | CISPLATIN INJ 0.5MG/ML · CISPLATIN INJ 1MG/ML · CISPLATIN INJECTION · CISPLATIN INJECTION BP · +4 more | 13 | 4 | Yes |
| Carboplatin | CARBOPLATIN INJECTION · CARBOPLATIN INJECTION BP · CARBOPLATIN INJECTION LIQ 10MG/ML · CARBOPLATIN INJECTION, BP · +2 more | 10 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more | 48 | 23 |
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XM | Enasidenib · Vorasidenib | 4 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OXALIPLATIN INJECTION called?
The same molecule, Oxaliplatin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Oxaliplatin Accord | Latin | Australia, Czechia |
| OXALIPLATIN KALCEKS | Latin | Czechia |
| Xaliptine | Latin | Saudi Arabia |
| OXALIPLATIN | Latin | Lebanon |
| OXALIPLATIN BAXTER | Latin | Australia |
| OXALIPLATIN KABI | Latin | Czechia |
| OXALIPLATIN TEVA | Latin | Czechia |
| OXALIPLATIN AGMED | Latin | Czechia |
| OXALIPLATIN EBEWE | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.